Aprea Therapeutics, Inc. SEC filings APRE
Aprea Therapeutics, Inc. has 446 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 29, 2026 | — |
| CORRESP | Letter to the SEC | Apr 27, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2026 | — |
| EFFECT | Filing | Mar 19, 2026 | — |
| CORRESP | Letter to the SEC | Mar 17, 2026 | — |
| CORRESP | Letter to the SEC | Mar 16, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2026 | — |
| EFFECT | Filing | Dec 29, 2025 | — |
| D | Filing | Dec 29, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2025 | — |
| EFFECT | Filing | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 25, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2024 | — |
| EFFECT | Filing | Feb 2, 2024 | — |
| CORRESP | Letter to the SEC | Jan 31, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2024 | — |
| EFFECT | Filing | Nov 30, 2020 | — |
| CORRESP | Letter to the SEC | Nov 25, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2020 | — |
| EFFECT | Filing | Oct 2, 2019 | — |
| CERT | Filing | Oct 2, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| 8-A12B | Filing | Sep 30, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 26, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 26, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 25, 2019 | — |
| CORRESP | Letter to the SEC | Sep 25, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 23, 2019 | — |
| CORRESP | Letter to the SEC | Sep 16, 2019 | — |
| DRS/A | Filing | Aug 20, 2019 | — |
| DRSLTR | Filing | Aug 20, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2019 | — |
| DRS | Filing | Jul 12, 2019 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Doylestown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1781983
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.